Success rate of current human-derived gastric cancer organoids establishment and influencing factors: A systematic review and meta-analysis

Figure 5 Forest plot of the pooled successful gastric cancer organoids culture rate according to different growth factor. A: Success rates with and without B27 supplementation: B27 group [68.7%, 95% confidence interval (CI): 46.9-83.3] vs non-B27 group (69.5%, 95%CI: 45.2-87.8) (P = 0.94); B-D: Success rates of gastric cancer organoids (GCOs) with N-acetylcystenine and gastrin but without nutlin-3 (71.9%, 95%CI: 38.2-96.2) compared to GCOs with nutlin-3 but without n-acetylcystenine and gastrin (71.5%, 95%CI: 59.3-82.3) (P = 0.95); E: Success rates of GCOs with fibroblast growth factor-2 (FGF-2) (67.4%, 95%CI: 21.6-99.2) compared to GCOs without FGF-2 (67.9%, 95%CI: 49.2-84.2) (P = 0.98); F: Success rates of GCOs with Y-27632 (58.2%, 95%CI: 41.6-75.0) compared to GCOs without Y-27632 (70.0%, 95%CI: 39.8-93.3) (P = 0.505). ES: Effect size; CI: Confidence interval; FGF-2: Fibroblast growth factor-2.